Can An Orphan Drug Be Approved Without Clinical Trial?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee will consider Orphan Europe's NDA for Carbaglu in NAGS deficiency, which is based on data from retrospective review of patient experience with carglumic acid
You may also be interested in...
Carbaglu Does Not Set Precedent For Orphan Drugs To Skip Trials, FDA Says
FDA is not setting a precedent by considering Orphan Europe's orphan drug Carbaglu for approval without a clinical trial, FDA's Office of Drug Evaluation III Director Julie Beitz indicated after the Endocrine and Metabolic Drugs Advisory Committee's Jan. 13 vote for approval
Carbaglu Does Not Set Precedent For Orphan Drugs To Skip Trials, FDA Says
FDA is not setting a precedent by considering Orphan Europe's orphan drug Carbaglu for approval without a clinical trial, FDA's Office of Drug Evaluation III Director Julie Beitz indicated after the Endocrine and Metabolic Drugs Advisory Committee's Jan. 13 vote for approval
FDA Advisory Committee Backs Approval Of Orphan Drug Without Controlled Clinical Trial
Patient experience with Orphan Europe's Carbaglu proves convincing, but panelists suggest registry to collect long-term safety data.